logo-loader
RNS
BrandShield Systems PLC

Brandshield Systems - Annual Pharma Fraud Report

RNS Number : 0783B
Brandshield Systems PLC
31 May 2023
 

31 May 2023

 

BrandShield Systems plc

("BrandShield," the "Company," or the "Group")

 

      BrandShield and Pharmaceutical Security Institute Issue Annual Pharma Fraud Report

 

     BrandShield successfully removed more than 434 rogue pharmacies

and 7,500 fraudulent drug listings in 2022

 

●      New report published by BrandShield and the Pharmaceutical Security Institute uncovers illicit drug trade and rogue pharmacies in 2022 

●      Indonesia and India continue to be the top source of illegal pharmaceutical sales and rogue pharmacies

 

BrandShield (AIM: BRSD), a leading provider of cybersecurity solutions for brand oriented digital risk protection ("DRP"), together with the Pharmaceutical Security Institute ("PSI"), is pleased to announce its annual Pharma Fraud report following a disruption programme carried out from January 2022 to January 2023 involving the monitoring, detecting, and removal of online threats.

 

The report highlights the extent of global criminal fraud targeting both innocent patients and pharmaceutical companies. The removed listings contained a variety of medicines relating to various cancers, HIV, and type 2 diabetes among others. Between January 2022 and January 2023, the cybersecurity firm analysed and removed hundreds of rogue pharmacies.

 

Over the 12-month period, BrandShield took down more than 7,500 fraudulent pharmaceutical listings across social media platforms, websites, and marketplaces, accounting for hundreds of thousands of dollars' worth of counterfeit drugs.

 

The report uncovered that Indonesia had the highest fraudulent listings, where more than 2,200 suspicious listings were removed. PSI is currently working with the various stakeholders and regulators to formulate a robust and efficient intel sharing platform.

 

Marketplace Listing Removals by Country

 

●      Indonesia - 2,218

●      India - 539

●      China - 190

●      Philippines - 118

●      Mexico - 53

●      Malaysia - 39

●      Venezuela - 30

●      Thailand - 20

●      United States - 16

●      Vietnam - 16

 

Pharma Fraud on Social Media

 

According to BrandShield's analysis, social media platforms were also a top target for pharmaceutical crime, where over 3,074 fake items were removed over the same 12-month period. Whilst the least compliant social media site stood out with only a 55% takedown rate, there was a massive improvement in the takedown rate overall, which increased by approximately 28% (from 63% to 81%).

 

Breakdown of Takedown Rate by Social Media Platform

 

●      YouTube - 95.8%

●      Facebook - 92%

●      Instagram - 86.7%

●      Pinterest - 67.3%

●      Twitter - 55%

 

Yoav Keren, Chief Executive Officer of BrandShield, commented:

 

"Year after year, cybercriminals continue to target consumers using counterfeit listings of potentially life-saving medications."

 

"Without adequate enforcement and proactive takedown efforts, fraudsters pose immense risks to public health. We're incredibly proud of our ongoing partnership with PSI to ensure consumers remain safe from physical and financial harm." 

 

C. Todd Ratcliffe, President and CEO of the Pharmaceutical Security Institute, added:

 

"The continued presence of illegal pharmaceutical sales on social media platforms and other websites underscores the need for ongoing vigilance and collaboration with key industry stakeholders."

 

"We look forward to continuing our partnership with BrandShield to safeguard consumers and the broader pharmaceutical industry at large from online threats and criminal activity."

 

 

Enquiries:

 

BrandShield Systems plc

Yoav Keren, CEO

 

+44 (0)20 3143 8300

Spark Advisory Partners Limited (Nominated Adviser)

Neil Baldwin / Andrew Emmott / James Keeshan

 

+44 (0)20 3368 3554

Shore Capital (Broker)

Toby Gibbs / James Thomas / Rachel Goldstein (Corporate Advisory)

Henry Willcocks (Corporate Broking)

 

Vigo Consulting (Financial Public Relations)

Jeremy Garcia / Kendall Hill

brandshield@vigoconsulting.com

 

+44 (0)20 7408 4090

 

 

 

 

+44 (0)20 7390 0237

 

 

 

 

 

About BrandShield

 

BrandShield is a leading cybersecurity company founded in Israel by cybersecurity experts that protects the world's largest brands and consumers from online scams, phishing attacks, impersonation, and other online threats posed by dangerous cybercriminals. Through its AI/ML platform, BrandShield identifies, tracks, and eliminates online threats for global brands and organizations, including Bristol Myers Squibb, Levi's, New Balance, Bang and Olufsen, The Sandbox, and the Pharmaceutical Security Institute. BrandShield is listed on the London Stock Exchange AIM under ticker symbol BRSD. To learn more about BrandShield, please visit the company website at https://www.brandshield.com/.

 

About Pharmaceutical Security Institute

 

Pharmaceutical Security Institute  is a non-profit trade association comprised of security directors from forty-two international research pharmaceutical manufacturers. PSI's principal mission is to address the problem of counterfeiting, illegal diversion, and major theft of pharmaceutical products to protect patient safety. PSI's principal activities include the collection, analysis, and dissemination of intelligence related to these criminal acts globally.

 

About Reach announcements

 

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABLGDURXXDGXG
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read